140 related articles for article (PubMed ID: 2407564)
1. The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study.
Fraser DI; Parsons A; Whitehead MI; Wordsworth J; Stuart G; Pryse-Davies J
Fertil Steril; 1990 Mar; 53(3):460-8. PubMed ID: 2407564
[TBL] [Abstract][Full Text] [Related]
2. Does low-dose, transdermal, norethisterone acetate reliably cause endometrial transformation in postmenopausal oestrogen-users?
Fraser D; Whitehead M; Schenkel L; Pryse-Davies J
Maturitas; 1993 Jan; 16(1):23-30. PubMed ID: 8429801
[TBL] [Abstract][Full Text] [Related]
3. Endometrial responses to transdermal estradiol in postmenopausal women.
Whitehead MI; Padwick ML; Endacott J; Pryse-Davies J
Am J Obstet Gynecol; 1985 Aug; 152(8):1079-84. PubMed ID: 4025456
[TBL] [Abstract][Full Text] [Related]
4. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology.
Ross AH; Boyd ME; Colgan TJ; Ferenczy A; Fugere P; Lorrain J
Obstet Gynecol; 1993 Nov; 82(5):773-9. PubMed ID: 8414325
[TBL] [Abstract][Full Text] [Related]
5. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women.
Brynhildsen J; Hammar M
Menopause; 2002; 9(2):137-44. PubMed ID: 11875333
[TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.
Archer DF; Furst K; Tipping D; Dain MP; Vandepol C
Obstet Gynecol; 1999 Oct; 94(4):498-503. PubMed ID: 10511348
[TBL] [Abstract][Full Text] [Related]
7. Transdermal administration of oestrogen/progestagen hormone replacement therapy.
Whitehead MI; Fraser D; Schenkel L; Crook D; Stevenson JC
Lancet; 1990 Feb; 335(8685):310-2. PubMed ID: 1967769
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
[TBL] [Abstract][Full Text] [Related]
9. Endometrial effects of transdermal estradiol/norethisterone acetate.
Lindgren R; Risberg B; Hammar M; Berg G; Pryse-Davies J
Maturitas; 1992 Aug; 15(1):71-8. PubMed ID: 1528133
[TBL] [Abstract][Full Text] [Related]
10. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
Johannisson E; Holinka CF; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
[TBL] [Abstract][Full Text] [Related]
11. Effects of oral continuous and transdermal cyclic 17-beta estradiol and norethindrone acetate replacement therapy on platelet aggregation in postmenopausal women.
Kaplan PB; Gücer F; Sayin NC; Yüce MA; Yardim T
J Reprod Med; 2002 Aug; 47(8):651-5. PubMed ID: 12216432
[TBL] [Abstract][Full Text] [Related]
12. Transdermal hormonal replacement therapy with transdermal progestin every second month.
Lindgren R; Risberg B; Hammar M; Berg G
Maturitas; 1995 Jun; 22(1):25-30. PubMed ID: 7666813
[TBL] [Abstract][Full Text] [Related]
13. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
14. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation.
Staland B
Maturitas; 1981 Aug; 3(2):145-56. PubMed ID: 7026979
[TBL] [Abstract][Full Text] [Related]
15. Norethindrone acetate and estradiol-induced endometrial hyperplasia.
Kurman RJ; Félix JC; Archer DF; Nanavati N; Arce J; Moyer DL
Obstet Gynecol; 2000 Sep; 96(3):373-9. PubMed ID: 10960628
[TBL] [Abstract][Full Text] [Related]
16. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels.
Eviö S; Tiitinen A; Turpeinen U; Ylikorkala O
Fertil Steril; 2000 Dec; 74(6):1080-3. PubMed ID: 11119731
[TBL] [Abstract][Full Text] [Related]
17. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
18. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
19. Endometrial and menstrual response to subcutaneous oestradiol and testosterone implants and continuous oral progestogen therapy in post-menopausal women.
Magos AL; Brincat M; O'Dowd T; Wardle PJ; Schlesinger P; Studd JW
Maturitas; 1985 Nov; 7(4):297-302. PubMed ID: 4079826
[TBL] [Abstract][Full Text] [Related]
20. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women.
Oosterbaan HP; van Buuren AH; Schram JH; van Kempen PJ; Ubachs JM; van Leusden HA; Beyer GP
Maturitas; 1995 Apr; 21(3):211-9. PubMed ID: 7616870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
